- Home
- BDRX vs BJDX Comparison
BDRX vs BJDX Comparison
Compare BDRX & BJDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDRX
- BJDX
- Stock Information
- Founded
- BDRX 2000
- BJDX 2015
- Country
- BDRX United Kingdom
- BJDX United States
- Employees
- BDRX N/A
- BJDX N/A
- Industry
- BDRX Biotechnology: Pharmaceutical Preparations
- BJDX Medical Specialities
- Sector
- BDRX Health Care
- BJDX Health Care
- Exchange
- BDRX Nasdaq
- BJDX Nasdaq
- Market Cap
- BDRX 2.4M
- BJDX 2.1M
- IPO Year
- BDRX N/A
- BJDX 2021
- Fundamental
- Price
- BDRX $3.71
- BJDX $3.45
- Analyst Decision
- BDRX
- BJDX
- Analyst Count
- BDRX 0
- BJDX 0
- Target Price
- BDRX N/A
- BJDX N/A
- AVG Volume (30 Days)
- BDRX 1.2M
- BJDX 43.6K
- Earning Date
- BDRX 04-21-2025
- BJDX 03-27-2025
- Dividend Yield
- BDRX N/A
- BJDX N/A
- EPS Growth
- BDRX N/A
- BJDX N/A
- EPS
- BDRX N/A
- BJDX N/A
- Revenue
- BDRX $104,895.00
- BJDX N/A
- Revenue This Year
- BDRX N/A
- BJDX N/A
- Revenue Next Year
- BDRX N/A
- BJDX N/A
- P/E Ratio
- BDRX N/A
- BJDX N/A
- Revenue Growth
- BDRX N/A
- BJDX N/A
- 52 Week Low
- BDRX $3.36
- BJDX $3.03
- 52 Week High
- BDRX $74.00
- BJDX $386.80
- Technical
- Relative Strength Index (RSI)
- BDRX 38.74
- BJDX 45.28
- Support Level
- BDRX $3.36
- BJDX $3.37
- Resistance Level
- BDRX $5.30
- BJDX $3.83
- Average True Range (ATR)
- BDRX 0.74
- BJDX 0.24
- MACD
- BDRX -0.08
- BJDX -0.00
- Stochastic Oscillator
- BDRX 5.99
- BJDX 24.00
About BDRX Biodexa Pharmaceuticals plc American Depositary Shs
Biodexa Pharmaceuticals PLC is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The company combines approved and developed medications with its proprietary and drug delivery technologies to provide compelling products that have the potential to powerfully impact the lives of patients.
About BJDX Bluejay Diagnostics Inc.
Bluejay Diagnostics Inc is a medical diagnostics company. It is developing rapid tests using whole blood using its Symphony technology platform to improve patient outcomes in critical care settings. The company's first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings and is a clinically established inflammatory biomarker for the assessment of the severity of infection and inflammation across many disease indications, including sepsis.